Dr. Reddy's Laboratories
RDY
14.89
+0.06
+0.40%
Dr. Reddy's Laboratories
US · RDY
#1451 by market cap
Listed 1970
14.89
+0.06
+0.40%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/11/11
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/10/30
-
Tonix Pharmaceuticals Files Patent Infringement Complaint Against Dr. Reddy's Laboratories On Nov 13, 2026; Seeks To Delay FDA Approval Of Dr. Reddy's Laboratories Anda Until Patent Expiration; Triggers Statutory Stay Of FDA Approval Of Dr. Reddy's...Benzinga · 2026/11/14
-
Rating change
BNP Paribas Initiates Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Announces Target Price $14.8Market Newswire · 2026/10/12
-
Rating change
BNP Paribas Upgrades Dr. Reddy's Laboratories to Outperform Neutral, $14.80 Price TargetMT Newswires · 2026/10/12
-
Rating change
Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450Benzinga · 2026/9/30
-
Jefferies Upgrades Dr. Reddy's Laboratories to Hold From Sell, Price Target Is $13.90MT Newswires · 2026/10/26
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/11/5
-
Rating change
Shaw and Partners Keeps Their Buy Rating on ReadyTech Holdings Ltd. (RDY)TipRanks · 2026/8/31
-
Rating change
Jefferies Initiates Dr. Reddy's Laboratories(RDY.US) With Hold Rating, Announces Target Price $13.89Market Newswire · 2026/10/26
-
Rating change
Analysts Offer Insights on Healthcare Companies: Zentek (OtherZTEKF) and Dr Reddy's Laboratories (RDY)TipRanks · 2026/10/1
-
Rating change
Morgans Sticks to Its Buy Rating for ReadyTech Holdings Ltd. (RDY)TipRanks · 2026/9/1
-
Company notice
Dr. Reddy's Laboratories | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/3
-
BofA Securities Maintains Dr. Reddy's Laboratories(RDY.US) With Buy RatingMarket Newswire · 2026/10/26
-
Form 144 | Dr. Reddy's Laboratories(RDY.US) Insider Proposes to Sell 6.54 Million in Common StocksMarket Newswire · 2026/11/3
-
Rating change
Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target Is INR1,283MT Newswires · 2026/7/10
-
Rating change
Jarden Remains a Buy on ReadyTech Holdings Ltd. (RDY)TipRanks · 2026/9/1
-
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer (related to financial reporting)SEC · 2026/10/26
-
Rating change
Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at BuyMT Newswires · 2026/6/22
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/11/4
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer (related to financial reporting)SEC · 2026/10/24
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/10/26
-
Rating change
BofA Securities Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $16.33Market Newswire · 2026/6/18
-
Dr Reddy's Laboratories Q2 2027 Earnings Call TranscriptBenzinga · 2026/10/23
-
Company notice
Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]SEC · 2026/10/29
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.
Dr. Reddy's Laboratories discussion 0 comments